Suchita Pakkala, MD
Dr. Suchita Pakkala, MD, is a board-certified hematologist and medical oncologist who specializes in treating breast cancer. She works with patients to understand their diagnosis and develop an individualized treatment plan based on the type and stage of their cancer and their overall health.
As a medical oncologist, Dr. Pakkala specializes in treatments such as chemotherapy, targeted therapy, immunotherapy, and hormone therapy. She works closely with breast surgeons, radiation oncologists, and other cancer specialists to provide coordinated care throughout treatment.
Dr. Pakkala earned her medical degree from the University of Tennessee and completed her internal medicine residency and fellowship in hematology and medical oncology at Emory University School of Medicine. She also holds a master’s degree in physiology from Georgetown University.
Dr. Pakkala is an Associate Professor of Hematology and Medical Oncology at Emory University School of Medicine. Her practice is primarily based at Winship Cancer Institute at Emory Midtown.
Board Certifications
American Board of Internal Medicine
Affiliations
Emory
Education & Training
- Medical School: University of Tennessee Health Science Center
- Internship: Emory University School of Medicine
- Residency: Emory University School of Medicine
Fellowships
Emory University School of Medicine
Locations and Directions
Correll Pavilion
Monday - Friday: 6 a.m. - 5:30 p.m.
Saturday: 7:30 a.m. - 3:30 p.m.
Publications
- A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
Osta BE, Carlisle J, Steuer C, Pakkala S, Leal T, Dhodapkar M, Liu Y, Chen Z, Owonikoko T, Ramalingam S
Clinical lung cancer. 2022;23(7):e400-e404.
PMID: 35863963 - A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease.
Higgins JP, Trinh AV, Watson ML, Beardslee T, Goyal S, Kudchadkar R, Pakkala S, Waltuck J, Momary K, Byers KF
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2022;28(7):338-345.
PMID: 35697040 - Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
Pakkala S, Higgins K, Chen Z, Sica G, Steuer C, Zhang C, Zhang G, Wang S, Hossain MS, Nazha B, Beardslee T, Khuri FR, Curran W, Lonial S, Waller EK, Ramalingam S, Owonikoko TK
Journal for immunotherapy of cancer. 2020;
PMID: 33428583 - Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.
Patel SP, Pakkala S, Pennell NA, Reckamp KL, Lanzalone S, Polli A, Tarazi J, Robert-Vizcarrondo F
The oncologist. 2020;25(7):562-e1012.
PMID: 32048771 - Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis.
Behera M, Steuer CE, Liu Y, Fernandez F, Fu C, Higgins KA, Gillespie TW, Pakkala S, Pillai RN, Force S, Belani CP, Khuri FR, Curran WJ, Ramalingam SS
The oncologist. 2020;25(6):e964-e975.
PMID: 31943520 - Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database.
Tian S, Zhang X, Jiang R, Pillai RN, Owonikoko TK, Steuer CE, Saba NF, Pakkala S, Patel PR, Belani CP, Khuri FR, Curran WJ, Ramalingam SS, Behera M, Higgins KA
Clinical lung cancer. 2019;20(6):484-493.e6.
PMID: 31296433 - Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
Mohamed A, Twardy B, Zordok MA, Ashraf K, Alkhoder A, Schrapp K, Steuer C, Chen Z, Pakkala S, Pillai R, Trad Wadsworth J, Higgins K, Beitler JJ, Ramalingam SS, Owonikoko TK, Khuri FR, Shin DM, Behera M, Saba NF
Head & neck. 2019;41(5):1490-1498.
PMID: 30835900 - Personalized therapy for lung cancer: striking a moving target.
Pakkala S, Ramalingam SS
JCI insight. 2018;
PMID: 30089719 - Immune checkpoint inhibitors in small cell lung cancer.
Pakkala S, Owonikoko TK
Journal of thoracic disease. 2018;10(Suppl 3):S460-S467.
PMID: 29593891 - Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, Khuri FR, Ahmed R, Ramalingam SS
Cancer. 2018;124(2):271-277.
PMID: 28960263
PLANNING
PREPARING FOR YOUR VISIT
Whether you’re a patient or you’re visiting one, a little planning beforehand can make your visit to Grady easier and more comfortable. Here, you’ll find everything you need to prepare for your visit, including an appointment checklist, admissions information, dining options, and much more.